Akero Therapeutics Showcases Innovative Treatments for Metabolic Diseases at BofA Securities Health Care Conference
Akero Therapeutics, a clinical-stage company based in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases that have high unmet medical needs. The company recently announced that its management will be presenting at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 5:00 p.m. Pacific Time in Las Vegas, Nevada. Those interested can tune into a live webcast of the presentation on the investor relations section of Akero Therapeutics’ website, [www.akerotx.com](http://www.akerotx.com). An archived replay will also be available on the website for those who miss the live broadcast.
Akero Therapeutics is currently focusing on developing treatments for metabolic diseases such as MASH (Metabolic Associated Fatty Liver Disease). The company’s lead product candidate, EFX, is undergoing evaluation in several Phase 3 clinical trials: SYNCHRONY Histology and SYNCHRONY Real-World studies for patients with pre-cirrhotic MASH (F2-F3 fibrosis) and MASH (F1-F3 fibrosis) or MASLD (Metabolic Associated Steatohepatitis with Liver Damage), respectively; and SYNCHRONY Outcomes study for patients with compensated cirrhosis due to MASH (F4 fibrosis). These studies build upon the positive results of the HARMONY and SYMMETRY Phase 2b clinical trials and are expected to provide further evidence of EFX’s efficacy in treating these conditions.
For investors looking to get in touch with Akero Therapeutics, they can reach out to Christina Tartaglia of Stern Investor Relations, Inc. at [212.362.1200](mailto:212.362.1200) or christina.tartaglia@sternir.com. For media inquiries, Sarah O’Connell can be contacted at [732.456
